At present, there is no dengue vaccine in India.
Yesterday, it was reported that Serum Institute of India was planning to seek approval to launch a drug to treat dengue virus.
According to reports, Serum has obtained rights from US-based Biotech Visterra to sell its dengue vaccine Monoclonal Antibody, VIS513.
"...Our government is sensible towards dengue virus, we are keeping a close watch on the prices of other medicines required for the treatment of the disease," Ahir said here while launching the revamped website of Department of Pharmaceuticals (DoP).
Meanwhile, Delhi is in the grip of its worst Dengue outbreak in five years. Till Monday 25 deaths were reported and 4,000 people affected from the disease.
Dengue spreads through infected Aedes or the tiger mosquitoes biting people. Most patients recover and on a minuscule number die from dengue.
Meanwhile, the Union Health Ministry has issued an advisory to Delhi government to "intensify" measures to check the breeding of mosquitoes.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
